Predicted Trait | |
Reported Trait | Breast cancer |
Mapped Trait(s) | breast carcinoma (EFO_0000305) |
Score Construction | |
PGS Name | PRS105_BC |
Development Method | |
Name | Genome-wide significant SNPs |
Parameters | r2 < 0.2 |
Variants | |
Original Genome Build | GRCh37 |
Number of Variants | 105 |
Effect Weight Type | beta |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000612 |
Citation (link to publication) | Gao C et al. J Clin Oncol (2021) |
Ancestry Distribution | |
Source of Variant Associations (GWAS) | European: 96.9% East Asian: 1.7% African: 1.2% Not Reported: 0.2% 317,507 individuals (100%) |
PGS Evaluation | European: 100% 1 Sample Sets |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
GWAS Catalog: GCST003845 Europe PMC: 27117709 |
19,291 individuals | European | NR |
GWAS Catalog: GCST001930 Europe PMC: 23535733 |
39,387 individuals | European | NR |
GWAS Catalog: GCST007302 Europe PMC: 23544012 |
8,211 individuals | European | NR |
GWAS Catalog: GCST000846 Europe PMC: 21060860 |
1,703 individuals | European | NR |
GWAS Catalog: GCST000162 Europe PMC: 18326623 |
548 individuals | European | NR |
GWAS Catalog: GCST002667 Europe PMC: 25342443 |
7,600 individuals | European | NR |
GWAS Catalog: GCST001420 Europe PMC: 22383897 |
5,242 individuals | East Asian | NR |
Europe PMC: 25855707 |
[ ,
0.0 % Male samples |
European | BCAC |
GWAS Catalog: GCST004950 Europe PMC: 25751625 |
33,864 individuals | European | NR |
Europe PMC: 24943594 |
[ ,
0.0 % Male samples |
European | BCAC |
GWAS Catalog: GCST000079 Europe PMC: 17903305 |
723 individuals | Not reported | NR |
GWAS Catalog: GCST001683 Europe PMC: 22976474 |
32,530 individuals | European | NR |
GWAS Catalog: GCST001683 Europe PMC: 22976474 |
3,748 individuals | African American or Afro-Caribbean | NR |
GWAS Catalog: GCST000678 Europe PMC: 20453838 |
8,556 individuals | European | NR |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM021102 | PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BRAC2 carriers younger than 40 years | OR: 18.2 [9.36, 35.4] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BRCA2 variant carriers vs non-carriers |
PPM021103 | PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among ATM carriers younger than 40 years | OR: 3.19 [2.51, 4.05] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in ATM variant carriers vs non-carriers |
PPM021104 | PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among CHEK2 carriers younger than 40 years | OR: 3.84 [3.12, 4.72] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in CHEK2 variant carriers vs non-carriers |
PPM021105 | PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among PALB2 carriers younger than 40 years | OR: 5.67 [3.84, 8.38] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in PALB2 variant carriers vs non-carriers |
PPM021101 | PSS011529| European Ancestry| 52,925 individuals |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Reported Trait: Breast cancer among BRAC1 carriers younger than 40 years | OR: 16.2 [8.1, 32.5] | — | — | — | Odds ratio is for a 1-SD change from the median PRS in BRCA1 variant carriers vs non-carriers |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS011529 | — | — | [ ,
0.0 % Male samples |
— | European | — | 11 cohorts
|
— |